Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.72
AEGR's Cash to Debt is ranked higher than
58% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. AEGR: 1.72 )
AEGR' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 1.72

Equity to Asset 0.38
AEGR's Equity to Asset is ranked higher than
57% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AEGR: 0.38 )
AEGR' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.79
Current: 0.38

0.38
0.79
F-Score: 6
Z-Score: 1.86
M-Score: 2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -16.86
AEGR's Operating margin (%) is ranked higher than
79% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. AEGR: -16.86 )
AEGR' s 10-Year Operating margin (%) Range
Min: -128.43   Max: -16.86
Current: -16.86

-128.43
-16.86
Net-margin (%) -24.87
AEGR's Net-margin (%) is ranked higher than
77% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. AEGR: -24.87 )
AEGR' s 10-Year Net-margin (%) Range
Min: -130.51   Max: -24.87
Current: -24.87

-130.51
-24.87
ROE (%) -30.34
AEGR's ROE (%) is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. AEGR: -30.34 )
AEGR' s 10-Year ROE (%) Range
Min: -105.89   Max: -28.82
Current: -30.34

-105.89
-28.82
ROA (%) -15.91
AEGR's ROA (%) is ranked higher than
76% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. AEGR: -15.91 )
AEGR' s 10-Year ROA (%) Range
Min: -189.06   Max: -14.07
Current: -15.91

-189.06
-14.07
ROC (Joel Greenblatt) (%) -575.55
AEGR's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. AEGR: -575.55 )
AEGR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -87419.35   Max: -839.03
Current: -575.55

-87419.35
-839.03
EBITDA Growth (3Y)(%) -21.90
AEGR's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AEGR: -21.90 )
AEGR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 20.3
Current: -21.9

0
20.3
EPS Growth (3Y)(%) -12.70
AEGR's EPS Growth (3Y)(%) is ranked higher than
72% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. AEGR: -12.70 )
AEGR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 1.7
Current: -12.7

0
1.7
» AEGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AEGR Guru Trades in Q1 2014

Michael Price 200,000 sh (New)
RS Investment Management Sold Out
Andreas Halvorsen Sold Out
» More
Q2 2014

AEGR Guru Trades in Q2 2014

Jim Simons 76,500 sh (New)
Michael Price 240,000 sh (+20.00%)
Steven Cohen 923,700 sh (unchged)
» More
Q3 2014

AEGR Guru Trades in Q3 2014

Joel Greenblatt 10,964 sh (New)
George Soros 25,000 sh (New)
Jim Simons 89,000 sh (+16.34%)
Michael Price 240,000 sh (unchged)
Steven Cohen 757,500 sh (-17.99%)
» More
Q4 2014

AEGR Guru Trades in Q4 2014

Steven Cohen 1,854,600 sh (+144.83%)
Steven Cohen 1,549,762 sh (+67.78%)
Steven Cohen 1,854,600 sh (unchged)
Steven Cohen 1,549,762 sh (unchged)
Joel Greenblatt Sold Out
George Soros Sold Out
Michael Price Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Aegerion Pharmaceuticals Inc

Three CEOs Reporting Large Insider Buys
Over the past week we’ve seen several large insider buys as well as several coming from the companies’ CEOs. It is interesting to note when a CEO, or even a CFO, buys because these insiders supposedly have the most intimate knowledge of their company's workings.

Read more...

Ratios

vs
industry
vs
history
Forward P/E 25.25
AEGR's Forward P/E is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AEGR: 25.25 )
N/A
P/B 4.50
AEGR's P/B is ranked higher than
72% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. AEGR: 4.50 )
AEGR' s 10-Year P/B Range
Min: 3.46   Max: 24.68
Current: 4.5

3.46
24.68
P/S 4.67
AEGR's P/S is ranked higher than
88% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. AEGR: 4.67 )
AEGR' s 10-Year P/S Range
Min: 3.86   Max: 1820.75
Current: 4.67

3.86
1820.75
EV-to-EBIT -21.83
AEGR's EV-to-EBIT is ranked higher than
58% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AEGR: -21.83 )
AEGR' s 10-Year EV-to-EBIT Range
Min: -38.4   Max: -10.3
Current: -21.83

-38.4
-10.3
Current Ratio 10.23
AEGR's Current Ratio is ranked higher than
88% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. AEGR: 10.23 )
AEGR' s 10-Year Current Ratio Range
Min: 0.09   Max: 28.72
Current: 10.23

0.09
28.72
Quick Ratio 9.99
AEGR's Quick Ratio is ranked higher than
88% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. AEGR: 9.99 )
AEGR' s 10-Year Quick Ratio Range
Min: 0.09   Max: 28.72
Current: 9.99

0.09
28.72
Days Inventory 163.59
AEGR's Days Inventory is ranked higher than
83% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AEGR: 163.59 )
AEGR' s 10-Year Days Inventory Range
Min: 59.63   Max: 141.61
Current: 163.59

59.63
141.61
Days Sales Outstanding 39.47
AEGR's Days Sales Outstanding is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. AEGR: 39.47 )
AEGR' s 10-Year Days Sales Outstanding Range
Min: 39.47   Max: 56.93
Current: 39.47

39.47
56.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.10
AEGR's Price/Net Cash is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 107.00 vs. AEGR: 6.10 )
AEGR' s 10-Year Price/Net Cash Range
Min: 5.02   Max: 21.5
Current: 6.1

5.02
21.5
Price/Net Current Asset Value 5.30
AEGR's Price/Net Current Asset Value is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. AEGR: 5.30 )
AEGR' s 10-Year Price/Net Current Asset Value Range
Min: 3.97   Max: 18.72
Current: 5.3

3.97
18.72
Price/Tangible Book 4.50
AEGR's Price/Tangible Book is ranked higher than
81% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. AEGR: 4.50 )
AEGR' s 10-Year Price/Tangible Book Range
Min: 3.9   Max: 21.76
Current: 4.5

3.9
21.76
Price/Median PS Value 0.30
AEGR's Price/Median PS Value is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. AEGR: 0.30 )
AEGR' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 2.34
Current: 0.3

0.21
2.34
Earnings Yield (Greenblatt) -4.70
AEGR's Earnings Yield (Greenblatt) is ranked higher than
72% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. AEGR: -4.70 )
AEGR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -7.7   Max: 0
Current: -4.7

-7.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KYE.Germany,
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
» More Articles for AEGR

Headlines

Articles On GuruFocus.com
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
Weekly CFO Buys Highlight: RXN, XBKS, STAG, AEGR, PZG Apr 02 2012 

More From Other Websites
Aegerion Pharmaceuticals to Announce First Quarter 2015 Financial Results on Monday, May 4 Apr 21 2015
Aegerion Pharmaceuticals to Announce First Quarter 2015 Financial Results on Monday, May 4 Apr 21 2015
Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside Apr 16 2015
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Apr 15 2015
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Apr 14 2015
Venture capitalists ride biotech wave one drug at a time Apr 10 2015
Venture capitalists ride biotech wave one drug at a time Apr 10 2015
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 09 2015
Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals' Board of Directors Apr 09 2015
Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals' Board of Directors Apr 09 2015
Aegerion Pharmaceuticals, Inc. (AEGR), Joint Corp (JYNT), Trillium Therapeutics Inc. (TRIL): Latest... Apr 02 2015
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 01 2015
Aegerion Pharmaceuticals Reaches Agreement With Sarissa Capital Mar 30 2015
Aegerion Pharmaceuticals Reaches Agreement With Sarissa Capital Mar 30 2015
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of... Mar 25 2015
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Mar 10 2015
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Mar 10 2015
AEGERION PHARMACEUTICALS, INC. Financials Mar 07 2015
10-K for Aegerion Pharmaceuticals, Inc. Mar 04 2015
AEGERION PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK